Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNXBTD)

• Drug Name: CEP-6331 Drug Info
• Synonyms: 2-Isopropoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CEP-6331; CHEMBL460990; BDBM24949; MolPort-027-637-287; ZINC33970297; 5-oxo dihydronaphthylcarbazole analogue, 16; X7365

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9823787
  TTD Drug ID: DMNXBTD

Molecule-Related Drug Atlas

Drug(s) Targeting Tropomyosin-related kinase A (TrkA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[2]
Repotrectinib	DM9FB2T	Non-small-cell lung cancer	2C25	Approved	[3]
Larotrectinib	DM26CQR	Solid tumour/cancer	2A00-2F9Z	Approved	[4]
MIM-D3	DMZHN5B	Alzheimer disease	8A20	Phase 3	[5]
SNA-120	DMPN314	Plaque psoriasis	EA90.0	Phase 2	[6]
CT 327	DMQXL1T	Plaque psoriasis	EA90.0	Phase 2	[7]
ONO-7579	DMXLPYE	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
Altiratinib	DMUJCBT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
PLX7486	DM0IVGU	Pancreatic cancer	2C10	Phase 1	[9]
DS-6051	DM0RD4F	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]

Drug(s) Targeting Vascular endothelial growth factor receptor 3 (FLT-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fruquintinib	DMHOSCQ	Colorectal cancer	2B91.Z	Approved	[11]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[12]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[13]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[14]
PI-88	DMGZPX6	Hepatocellular carcinoma	2C12.02	Phase 3	[15]
Taberminogene vadenovec	DMW5PHL	Vascular restinosis	BE2Z	Phase 3	[16]
ABT-869	DMREDYP	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[18]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[19]
VATALANIB	DMY0UEQ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[20]

Drug(s) Targeting Mixed lineage kinase 3 (MAP3K11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
URMC-099	DMCJXWK	Discovery agent	N.A.	Investigative	[21]
CEP-5104	DMV43GY	Discovery agent	N.A.	Investigative	[1]
CEP1349	DMOAZX5	Discovery agent	N.A.	Investigative	[22]
PMID24044867C8	DML4KMP	Discovery agent	N.A.	Investigative	[21]

Drug(s) Targeting Fyn tyrosine protein kinase (FYN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[23]
JNJ-26483327	DMSQ3AZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[24]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[25]
PMID15546730C2	DMOPUIH	Discovery agent	N.A.	Investigative	[26]
CEP-5104	DMV43GY	Discovery agent	N.A.	Investigative	[1]
JNJ-10198409	DM9GDP5	Discovery agent	N.A.	Investigative	[27]
1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane	DMD7WNV	Discovery agent	N.A.	Investigative	[28]

Drug(s) Targeting Mixed lineage kinase 1 (MAP3K9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CEP1347	DMXCD69	Asthma	CA23	Phase 2/3	[22]
URMC-099	DMCJXWK	Discovery agent	N.A.	Investigative	[21]
CEP-5104	DMV43GY	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Mixed lineage kinase 2 (MAP3K10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
URMC-099	DMCJXWK	Discovery agent	N.A.	Investigative	[21]
CEP-5104	DMV43GY	Discovery agent	N.A.	Investigative	[1]
CEP1348	DMA7JO4	Discovery agent	N.A.	Investigative	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fyn tyrosine protein kinase (FYN)	TT2B9KF	FYN_HUMAN	Inhibitor	[1]
Mixed lineage kinase 1 (MAP3K9)	TTUNSIX	M3K9_HUMAN	Inhibitor	[1]
Mixed lineage kinase 2 (MAP3K10)	TT9FN4J	M3K10_HUMAN	Inhibitor	[1]
Mixed lineage kinase 3 (MAP3K11)	TTETX6Q	M3K11_HUMAN	Inhibitor	[1]
Tropomyosin-related kinase A (TrkA)	TTTDVOJ	NTRK1_HUMAN	Inhibitor	[1]
Vascular endothelial growth factor receptor 3 (FLT-4)	TTDCBX5	VGFR3_HUMAN	Inhibitor	[1]

References

• [1] Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [5] Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
• [8] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [9] National Cancer Institute Drug Dictionary (drug id 747694).
• [10] National Cancer Institute Drug Dictionary (drug id 766123).
• [11] Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [13] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [14] Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
• [15] Company report (Medigen)
• [16] Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
• [17] Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814).
• [19] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [20] Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
• [21] Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48.
• [22] Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
• [23] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [24] National Cancer Institute Drug Dictionary (drug id 596693).
• [25] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
• [26] Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
• [27] (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
• [28] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.